iBio (NYSE American:IBIO) provided an updated on its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron variant of SARS-CoV-2. According to the WHO, the Omicron variant has at...
iBio (NYSEA:IBIO) and the University of Texas Southwestern Medical Center entered into a research collaboration to explore in solid tumors the anti-cancer potential of the molecule that is part of the IBIO-100 program...
iBio (NYSEA:IBIO) purchased the manufacturing facility it previously operated under a lease from two affiliates of Eastern Capital and also acquired the approximate 30% equity interest in iBio CDMO held by the...
William (Chip) Clark iBio (NYSE:IBIO) appointed William (Chip) Clark to the board, effective immediately. Mr. Clark has more than 30 years of biotechnology and pharmaceutical experience, with a focus on business...
iBio (NYSEA:IBIO) bolstered its immuno-oncology pipeline with the acquisition of exclusive rights to develop and commercialize the anti-CD25 monoclonal antibody, RTX-003, from RubrYc. The partnership also includes an...
The advantages of iBio’s (NYSE American:IBIO) plant-based drug production system was featured in the Aug. 4 edition of Genetic Engineering & Biotechnology News. The article quoted Randy Maddux, COO of iBio, who...
iBio (NYSE American:IBIO) announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid (N) protein of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T...
In a major step towards leveraging the speed and throughput of its proprietary, plant-based FastPharming protein expression system, iBio (NYSE American:IBIO) is adding three anti-cancer targets to its pipeline of...
Evert Schimmelpennink iBio (NYSEA:IBIO) appointed Evert (Eef) Schimmelpennink to its board of directors, effective immediately. In an executive leadership career spanning more than 20 years, Mr. Schimmelpennink has...
iBio (NYSE American:IBIO) updated its IBIO-201 program and reported progress in developing a second-generation subunit vaccine candidate, IBIO-202, being designed for the prevention of SARS-CoV-2 infection. IBIO-201...